Research has shown that the Quantum® Cell Expansion System is capable of producing high-titer retroviruses, including lentivirus, at titers comparable to those of flask-based processes (2 × 108 particles), with a dramatic reduction in labor and a substantial increase in yield.1
Current studies are also exploring the feasibility of producing adeno-associated virus (AAV8, AAV9). The Quantum system's ability to automate the manual cell culture process makes it a powerful tool for carrying out plasmid transfections and viral transductions in a functionally closed system while aiding in the current good manufacturing practice (cGMP) compliance of the manufacturing process.
From preclinical application to clinical trials or commercialization, whether your company is a startup or an industry leader, we look forward to supporting your process and helping you prepare for the road ahead.
1Sheu J, et al., "Large-Scale Production of Clinical Grade Lentiviral Vector for Induced Pluripotent Stem Cell Induction in a Hollow-Fiber Bioreactor." 2014 ASGCT 17th Annual Meeting. Washington D.C., USA. 23 May 2014. Poster [728].
Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.